Genetic Testing
Screening Method for Lynch Syndrome in Endometrial and Ovarian Cancer
Recruiting1 award8 criteria
Toronto, Ontario
This trial will test a new way of identifying women with Lynch Syndrome, a hereditary disease that can lead to cancer. If successful, it could improve screening and surgery options for women at risk.
Monoclonal Antibodies
Disitamab Vedotin for HER2-Positive Cancer
Recruiting1 awardPhase 2
Norwich, Connecticut
This trial is testing a new drug called disitamab vedotin (DV) on patients with advanced or metastatic cancers that have a specific marker called HER2. The drug works by finding and attaching to cancer cells, then delivering a substance to kill them. The study aims to see if DV is effective and safe for these patients. Disitamab vedotin is an antibody-drug conjugate designed for targeting HER2 that has been approved for urothelial carcinoma and gastric cancer.
Hormone Therapy
Levonorgestrel IUS + Everolimus for Endometrial Cancer
Recruiting1 awardPhase 2
Greeley, Colorado
This trial tests a hormone-releasing device inside the uterus, alone or with a drug called everolimus, for patients with pre-cancerous growths or early-stage uterine cancer. The device releases a hormone to control cell growth, while everolimus helps stop cancer cells from growing. Everolimus has shown promising results for various types of cancer, including breast cancer.
Anti-diabetic drug
Everolimus + Letrozole + Metformin for Endometrial Cancer
Recruiting1 awardPhase 2
Pensacola, Florida
This trial will test if everolimus, letrozole, and metformin can help control endometrial cancer that has come back or is progressing. Researchers will also study if the combination is safe.
mTOR inhibitor
Everolimus + Letrozole for Endometrial Cancer
Recruiting1 awardPhase 2
Morristown, New Jersey
This trial will test if a combination of everolimus and letrozole can help control endometrial cancer that has come back or is progressing. The safety of this drug combination will also be studied.
Aromatase Inhibitor
Exemestane for Endometrial Cancer
Recruiting1 awardPhase 2
Birmingham, Alabama
This trial looks at how well exemestane works in treating patients with endometrial cancer or abnormal cell growth in the endometrium. Exemestane may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Popular Filters
Trials for Adenocarcinoma Patients
HIF-2alpha Inhibitor
Triple Drug Combo for Solid Cancers
Recruiting1 awardPhase 2
Duarte, California
This trial is testing a new treatment combining three drugs to help patients with difficult-to-treat cancers. The treatment aims to stop cancer growth, help the immune system fight the cancer, and cut off the blood supply to tumors.
Small Molecule Inhibitor
LY3537982 for Cancer
Recruiting1 awardPhase 1 & 2
Indianapolis, Indiana
This trial is testing a new drug called LY3537982 in cancer patients with the KRAS G12C mutation. It targets this mutation to stop cancer cells from growing. The study includes patients who haven't responded to other treatments or cannot tolerate them. LY3537982 is a new drug targeting the KRAS G12C mutation, similar to previously approved drugs like sotorasib and adagrasib.
AH-HA EHR Tool for Heart Health in Cancer Survivors
Recruiting1 award6 criteria
Cedar Rapids, Iowa
This trial is looking at the effects of a tool that uses electronic health records to help cancer survivors manage their cardiovascular health. The study will compare how well the tool works compared to usual care in terms of risk reduction and health promotion activities.
Trials for Uterine Cancer Patients
Alkylating Agent
Veliparib + Chemotherapy for Advanced Cancer
Recruiting1 awardPhase 1
Duarte, California
This trial is studying the side effects and best dose of veliparib when given with paclitaxel and carboplatin to treat patients with solid tumors that have spread or cannot be removed by surgery and have liver or kidney dysfunction.
Trials for Metastatic Patients
Monoclonal Antibodies
SGN-B7H4V for Advanced Cancers
Recruiting1 awardPhase 1
Denver, Colorado
This trial tests a new drug called SGN-B7H4V for safety and side effects in patients with advanced or metastatic solid tumors. It aims to find the right dosage and see if the drug can effectively treat their cancer.
Alkylating agents
Immunotherapy vs Chemotherapy for Endometrial Cancer
Recruiting2 awardsPhase 3
Miami Beach, Florida
This trial is testing whether the immunotherapy drug pembrolizumab is better than the standard chemotherapy treatment for women with endometrial cancer that is resistant to other treatments.
Monoclonal Antibodies
MK-7684A for Advanced Cancers
Recruiting1 awardPhase 2
Duarte, California
This trial is testing a new treatment that combines two medications to see if it works better than the current treatment for serious cancers, particularly cervical cancer. One of the medications has shown promising results in treating various cancers, including cervical cancer. The goal is to find out if this combination can improve patient outcomes by helping the immune system fight cancer more effectively.
HIF-2alpha Inhibitor
Triple Drug Combo for Solid Cancers
Recruiting1 awardPhase 2
Duarte, California
This trial is testing a new treatment combining three drugs to help patients with difficult-to-treat cancers. The treatment aims to stop cancer growth, help the immune system fight the cancer, and cut off the blood supply to tumors.
Small Molecule Inhibitor
LY3537982 for Cancer
Recruiting1 awardPhase 1 & 2
Indianapolis, Indiana
This trial is testing a new drug called LY3537982 in cancer patients with the KRAS G12C mutation. It targets this mutation to stop cancer cells from growing. The study includes patients who haven't responded to other treatments or cannot tolerate them. LY3537982 is a new drug targeting the KRAS G12C mutation, similar to previously approved drugs like sotorasib and adagrasib.
Checkpoint Inhibitor
Pembrolizumab + Chemotherapy/Radiotherapy for Endometrial Cancer
Recruiting1 awardPhase 3
Mobile, Alabama
This trial is testing if adding the immunotherapy drug pembrolizumab to standard chemotherapy and radiation improves disease-free survival and overall survival in patients with non-small cell lung cancer.
Trials for ER Positive Patients
CDK4/6 Inhibitor
Abemaciclib + Letrozole for Endometrial Cancer
Recruiting1 awardPhase 2
Mobile, Alabama
This trial is testing a new cancer drug to see if it stops the disease from progressing in women with endometrioid endometrial cancer. Treatment will continue until the patient experiences side effects, the disease progresses, or they request to stop.
Phase 3 Trials
Alkylating agents
Immunotherapy vs Chemotherapy for Endometrial Cancer
Recruiting2 awardsPhase 3
Miami Beach, Florida
This trial is testing whether the immunotherapy drug pembrolizumab is better than the standard chemotherapy treatment for women with endometrial cancer that is resistant to other treatments.
Checkpoint Inhibitor
Pembrolizumab + Chemotherapy/Radiotherapy for Endometrial Cancer
Recruiting1 awardPhase 3
Mobile, Alabama
This trial is testing if adding the immunotherapy drug pembrolizumab to standard chemotherapy and radiation improves disease-free survival and overall survival in patients with non-small cell lung cancer.
Trials With No Placebo
Monoclonal Antibodies
SGN-B7H4V for Advanced Cancers
Recruiting1 awardPhase 1
Denver, Colorado
This trial tests a new drug called SGN-B7H4V for safety and side effects in patients with advanced or metastatic solid tumors. It aims to find the right dosage and see if the drug can effectively treat their cancer.
Alkylating agents
Immunotherapy vs Chemotherapy for Endometrial Cancer
Recruiting2 awardsPhase 3
Miami Beach, Florida
This trial is testing whether the immunotherapy drug pembrolizumab is better than the standard chemotherapy treatment for women with endometrial cancer that is resistant to other treatments.
Monoclonal Antibodies
MK-7684A for Advanced Cancers
Recruiting1 awardPhase 2
Duarte, California
This trial is testing a new treatment that combines two medications to see if it works better than the current treatment for serious cancers, particularly cervical cancer. One of the medications has shown promising results in treating various cancers, including cervical cancer. The goal is to find out if this combination can improve patient outcomes by helping the immune system fight cancer more effectively.
HIF-2alpha Inhibitor
Triple Drug Combo for Solid Cancers
Recruiting1 awardPhase 2
Duarte, California
This trial is testing a new treatment combining three drugs to help patients with difficult-to-treat cancers. The treatment aims to stop cancer growth, help the immune system fight the cancer, and cut off the blood supply to tumors.
Small Molecule Inhibitor
LY3537982 for Cancer
Recruiting1 awardPhase 1 & 2
Indianapolis, Indiana
This trial is testing a new drug called LY3537982 in cancer patients with the KRAS G12C mutation. It targets this mutation to stop cancer cells from growing. The study includes patients who haven't responded to other treatments or cannot tolerate them. LY3537982 is a new drug targeting the KRAS G12C mutation, similar to previously approved drugs like sotorasib and adagrasib.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.